^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
GSK5764227
i
Other names: GSK-5764227, GSK’227, GSK5764227, HS-20093, HS20093, HS 20093, GSK 5764227
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
GSK, Jiangsu Hansoh Pharma
Drug class:
Topoisomerase I inhibitor, B7-H3-targeted antibody-drug conjugate
Related drugs:
20d
A Study of GSK5764227 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=240, Recruiting, GlaxoSmithKline | Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2026 --> Jul 2026
Enrollment open • Trial primary completion date • Metastases
|
topotecan • GSK5764227
27d
ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma. (clinicaltrials.gov)
P1, N=448, Not yet recruiting, Hansoh BioMedical R&D Company
New P1 trial • Combination therapy
|
Focus V (anlotinib) • epirubicin • Ariely (adebrelimab) • GSK5764227
1m
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=141, Recruiting, GlaxoSmithKline | Trial completion date: Oct 2026 --> Sep 2028 | Trial primary completion date: Oct 2026 --> Sep 2028
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Jemperli (dostarlimab-gxly) • belrestotug (EOS-448) • GSK5764227 • nelistotug (GSK6097608)
2ms
ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer (clinicaltrials.gov)
P3, N=460, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting
Enrollment open
|
topotecan • GSK5764227
3ms
Phase Ib Trial of HS-20117 in Combination with Other Drugs in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=780, Not yet recruiting, Hansoh BioMedical R&D Company
New P1 trial
|
BRAF (B-raf proto-oncogene)
|
cisplatin • carboplatin • 5-fluorouracil • GSK5764227 • PM1080
3ms
A Study of GSK5764227 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=260, Not yet recruiting, GlaxoSmithKline | N=100 --> 260
Enrollment change • Metastases
|
topotecan • GSK5764227
4ms
A Study of GSK5764227 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=100, Not yet recruiting, GlaxoSmithKline
New P1 trial • Metastases
|
topotecan • GSK5764227
5ms
A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer (clinicaltrials.gov)
P3, N=406, Not yet recruiting, Hansoh BioMedical R&D Company
New P3 trial
|
GSK5764227
5ms
ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=610, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy • Metastases
|
Erbitux (cetuximab) • cisplatin • carboplatin • Xtandi (enzalutamide) • Ariely (adebrelimab) • GSK5764227
5ms
ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer (clinicaltrials.gov)
P3, N=460, Not yet recruiting, Hansoh BioMedical R&D Company
New P3 trial
|
topotecan • GSK5764227
9ms
ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=610, Not yet recruiting, Hansoh BioMedical R&D Company
New P1 trial • Combination therapy • Metastases
|
Erbitux (cetuximab) • cisplatin • carboplatin • Xtandi (enzalutamide) • Ariely (adebrelimab) • GSK5764227
10ms
ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=0, Withdrawn, Hansoh BioMedical R&D Company | N=50 --> 0 | Not yet recruiting --> Withdrawn
Enrollment change • Trial withdrawal
|
GSK5764227
10ms
ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
P2, N=50, Not yet recruiting, Hansoh BioMedical R&D Company | Initiation date: Nov 2023 --> Nov 2024
Trial initiation date
|
GSK5764227
10ms
ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
P2, N=120, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting | Initiation date: Sep 2023 --> Jan 2024
Enrollment open • Trial initiation date • Metastases
|
GSK5764227
10ms
ARTEMIS-005: HS-20093 in Patients With Advanced Esophageal Carcinoma and Other Advanced Solid Tumors (clinicaltrials.gov)
P2, N=220, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting
Enrollment open
|
GSK5764227
10ms
ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors (clinicaltrials.gov)
P2, N=170, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting
Enrollment open
|
GSK5764227
10ms
B7-H3 Inhibitors in Oncology Clinical Trials: A Review. (PubMed, J Immunother Precis Oncol)
Particularly promising treatments are enoblituzumab for prostate cancer, 131I-omburtamab for central nervous system malignancies, and HS-20093 for small-cell lung cancer but further studies are warranted. These data will be telling of the efficacy of B7-H3 inhibitors in both hematologic and solid malignancies. This study aimed to compile available results of B7-H3 inhibitors in oncology clinical trials.
Review • Journal
|
CD276 (CD276 Molecule)
|
GSK5764227 • Omblastys (131I-omburtamab) • enoblituzumab (MGA271)
1year
Phase 2 Study of HS-20093 in Patients With Advanced Esophageal Carcinoma and Other Advanced Solid Tumors (clinicaltrials.gov)
P2, N=220, Not yet recruiting, Hansoh BioMedical R&D Company
New P2 trial • Metastases
|
GSK5764227
1year
B7-H3/CD276 and small-cell lung cancer: What's new? (PubMed, Transl Oncol)
The addition of an anti-PD-L1, atezolizumab or durvalumab, to platinum/etoposide regimen became the standard of care for first-line therapy of extensive-stage (ES)-SCLC with the 12 months median survival exceeded for the first time. The most promising preliminary clinical results have been reported by DS7300a and HS-20093, both are antibody-drug conjugates, that are under investigation in ongoing trials for the treatment of pretreated SCLC. This review will provide an overview of B7-H3 and corresponding inhibitors and the clinical development in the management of SCLC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD276 (CD276 Molecule)
|
CD276 expression
|
Tecentriq (atezolizumab) • Imfinzi (durvalumab) • etoposide IV • ifinatamab deruxtecan (DS-7300) • GSK5764227
over1year
ARTEMIS-002 TRIAL IN PROGRESS: A MULTI-CENTER PHASE II TRIAL ASSESSING HS-20093 (B7-H3 ANTIBODY-DRUG CONJUGATE) FOR RELAPSED OR REFRACTORY OSTEOSARCOMA AND OTHER SARCOMAS (CTOS 2023)
N/A Now the trial is enrolling.
Clinical • P2 data • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD276 (CD276 Molecule)
|
PD-L1 expression
|
GSK5764227
over1year
ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas (clinicaltrials.gov)
P2, N=170, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting
Enrollment open
|
GSK5764227
almost3years
A Study of the HS-20093 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=177, Recruiting, Shanghai Hansoh Biomedical Co., Ltd
New P1 trial
|
CD276 (CD276 Molecule)
|
CD276 expression
|
GSK5764227
Share via
